Boiron reports net income up 23.5% to 15.5 million euros, thanks to higher interest rates which boosted its investment income, but operating income down 11.1% to 17.8 million, for the first half of 2023.

Its gross margin fell from 67.1% to 72.9% year-on-year, following lower sales of Covid tests, for total sales down 6.6% to 239.9 million, also due to lower sales of non-proprietary homeopathic medicines in France.

For 2023, Boiron estimates that its sales could post a slight decline, but that given the change in product mix and the exceptional adjustments linked to ABBI already booked, its operating income could rise.

Copyright (c) 2023 CercleFinance.com. All rights reserved.